[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2018, 68(6):394-424. [2] Chinn SB, Myers JN. Oral cavity carcinoma: Current management, controversies, and future directions [J]. J Clin Oncol, 2015, 33(29):3269-3276. [3] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 [J]. Int J Cancer, 2015, 136(5):E359-E386. [4] Thompson-Harvey A, Yetukuri M, Hansen AR, et al. Rising incidence of late-stage head and neck cancer in the United States [J]. Cancer, 2019, 126(5):1090-1101. [5] Maekawa A, Ishihara R, Iwatsubo T, et al. High incidence of head and neck cancers after endoscopic resection for esophageal cancer in younger patients [J]. J Gastroenterol, 2020, 55(4):401-407. [6] Moeckelmann N, Ebrahimi A, Tou YK, et al. Prognostic implications of the 8th edition American Joint Committee on Cancer (AJCC) staging system in oral cavity squamous cell carcinoma [J]. Oral Oncol, 2018, 85:82-86. [7] Wang Y, Wang P, Andrukhov O, et al. Meta-analysis of the prognostic value of the neutrophil-to-lymphocyte ratio in oral squamous cell carcinoma [J]. J Oral Pathol Med, 2018, 47(4):353-358. [8] Zhang Y, Zheng L, Quan L, et al. Prognostic role of platelet-to-lymphocyte ratio in oral cancer: A meta-analysis [J]. J Oral Pathol Med, 2021, 50(3):274-279. [9] Diao P, Wu Y, Li J, et al. Preoperative systemic immune-inflammation index predicts prognosis of patients with oral squamous cell carcinoma after curative resection [J]. J Transl Med, 2018, 16(1):365. [10] Balachandran VP, Gonen M, Smith JJ, et al. Nomograms in oncology: more than meets the eye [J]. Lancet Oncol, 2015, 16(4):e173-e180. [11] Wang XH, Long LH, Cui Y, et al. MRI-based radiomics model for preoperative prediction of 5-year survival in patients with hepatocellular carcinoma [J]. Br J Cancer, 2020, 122(7):978-985. [12] Thurtle DR, Jenkins V, Pharoah PD, et al. Understanding of prognosis in non-metastatic prostate cancer: a randomised comparative study of clinician estimates measured against the PREDICT prostate prognostic model [J]. Br J Cancer, 2019, 121(8):715-718. [13] Mattavelli D, Lombardi D, Missale F, et al. Prognostic Nomograms in oral squamous cell carcinoma: The negative impact of low neutrophil to lymphocyte ratio [J]. Front Oncol, 2019, 9:339. [14] Wang F, Zhang H, Wen J, et al. Nomograms forecasting long-term overall and cancer-specific survival of patients with oral squamous cell carcinoma [J]. Cancer Med, 2018, 7(4):943-952. [15] Shi H, Jiang Y, Cao H, et al. Nomogram based on systemic immune-inflammation index to predict overall survival in gastric cancer patients [J]. Dis Markers, 2018, 2018:1787424. [16] Zhang K, Hua Y, Wang D, et al. Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer [J]. J Transl Med, 2019, 17(1):30. [17] Huang H, Liu Q, Zhu L, et al. Prognostic value of preoperative systemic immune-inflammation index in patients with cervical cancer [J]. Sci Rep, 2019, 9(1):3284. [18] Kao H, Löfstrand J, Loh CY, et al. Nomogram based on albumin and neutrophil-to-lymphocyte ratio for predicting the prognosis of patients with oral cavity squamous cell carcinoma [J]. Sci Rep, 2018, 8(1):13081. [19] Shaul ME, Fridlender ZG. Cancer-related circulating and tumor-associated neutrophils-subtypes, sources and function [J]. FEBS J, 2018, 285(23):4316-4342. [20] Granot Z, Fridlender ZG. Plasticity beyond cancer cells and the "immunosuppressive switch" [J]. Cancer Res, 2015, 75(21):4441-4445. [21] Ankus E, Price SJ, Ukoumunne OC, et al. Cancer incidence in patients with a high normal platelet count: a cohort study using primary care data [J]. Fam Pract, 2018, 35(6):671-675. [22] Huong PT, Nguyen LT, Nguyen XB, et al. The role of platelets in the tumor-microenvironment and the drug resistance of cancer cells [J]. Cancers (Basel), 2019, 11(2):240. [23] Chater C, Bauters A, Beugnet C, et al. Intraplatelet vascular endothelial growth factor and platelet-derived growth factor: New biomarkers in carcinoembryonic antigen-negative colorectal cancer? [J]. Gastrointestinal Tumors, 2018, 5(1-2):32-37. [24] Ray-Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas[J]. Cancer Res, 2009, 69(13):5383-5391. [25] Crocenzi T, Cottam B, Newell P, et al. A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma [J]. J Immunother Cancer, 2016, 4:45. [26] Mehrazin R, Uzzo RG, Kutikov A, et al. Lymphopenia is an independent predictor of inferior outcome in papillary renal cell carcinoma [J]. Urol Oncol, 2015, 33(9):388.e19-25. [27] Ho AS, Kim S, Tighiouart M, et al. Metastatic lymph node burden and survival in oral cavity cancer [J]. J Clin Oncol, 2017, 35(31):3601-3609. [28] Rajappa SK, Maheshwari U, Jaipuria J, et al. Number of positive nodes-current relevance in determining prognosis of oral cavity cancer after the recent AJCC staging update [J]. Oral Oncology, 2019, 90:1-5. |